Patients participating in clinical trials for anticancer drugs do not gain a survival benefit compared with individuals who received routine care, according to study results published in JAMA.Although trial participants had significantly improved OS when researchers performed a pooled analysis of all the studies evaluated, those benefits diminished when they focused solely on high-quality trials,
/PRNewswire/ New research in the December 2021 issue of JNCCN Journal of the National Comprehensive Cancer Network found that only 59% of oncology clinical.